Prognostic factors in ductal pancreatic cancer

C. J. Yeo, J. L. Cameron

Research output: Contribution to journalReview articlepeer-review

Abstract

Introduction: The diagnosis of pancreatic adenocarcinoma remains a devastating life event for most patients and their families. Many patients with this relatively common malignancy present at a stage of disease not amenable to cancer-directed resectional therapy, and are treated via nonoperative palliative measures, with median survival of 4-8 months post- diagnosis. Conclusion: A minority of patients present with disease limited to the pancreas and periampullary region and are candidates for resectional therapy. The prognosis for these patients is determined by several factors: clinicopathologic staging, tumor biology and molecular genetics, perioperative factors and the use of postoperative adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)129-133
Number of pages5
JournalLangenbeck's Archives of Surgery
Volume383
Issue number2
DOIs
StatePublished - Apr 1998

Keywords

  • Adjuvant chemoradiation therapy
  • Pancreatic adenocarcinoma
  • Tumor DNA content
  • p53 tumor suppressor gene

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Prognostic factors in ductal pancreatic cancer'. Together they form a unique fingerprint.

Cite this